ArticleNPJ breast cancer2019
Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression.
Article in NPJ breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 60 citations in OpenAlex.
- Development and testing of a random forest-based machine learning model for predicting events among breast cancer patients with a poor response to neoadjuvant chemotherapy.European journal of medical research · 2023Trial
- Reclassification ofCurrent oncology (Toronto, Ont.) · 2026Article
- Etiology of gene expression-based subtypes of breast cancer in the Ghana Breast Health Study.International journal of cancer · 2026Article
- Elucidating cooperative genetic events in DCIS progression in mutantProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Emerging Breast Cancer Subpopulations: Functional Heterogeneity Beyond the Classical Subtypes.International journal of molecular sciences · 2025Review
- Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancer.Histopathology · 2025Article
- Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes.Journal of the National Cancer Institute · 2025Article
- Contribution of Prediagnostic Host Factors to Shaping the Stromal Microenvironment of Breast Cancer among Sub-Saharan African Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Biological correlates associated with high-risk breast cancer patients identified using a computational method.NPJ breast cancer · 2025Article
- The Genomic and Biologic Landscapes of Breast Cancer and Racial Differences.International journal of molecular sciences · 2024Review
- Risk factors for breast cancer subtypes by race and ethnicity: a scoping review.Journal of the National Cancer Institute · 2024Article
- Prognostic prediction for HER2-low breast cancer patients using a novel machine learning model.BMC cancer · 2024Article
- Clinical Relevance ofCancers · 2024Article
- Risk factors for breast cancer subtypes by race and ethnicity: A scoping review of the literature.medRxiv : the preprint server for health sciences · 2024Article
- Gene expression and anticancer evaluation of Kigelia africana (Lam.) Benth. Extracts using MDA-MB-231 and MCF-7 cell lines.PloS one · 2024Article
- Significant association of BRCA1 (rs1799950), BRCA2 (rs144848) and TP53 (rs1042522) polymorphism with breast cancer risk in Pashtun population of Khyber Pakhtunkhwa, Pakistan.Molecular biology reports · 2023Article
- Positive p53 Expression Is Associated with Primary Endocrine Therapy Resistance in Locally Advanced Stage Luminal B HER2-Negative Breast Cancer Patients: A Cross-Sectional Study in Indonesia.Diagnostics (Basel, Switzerland) · 2023Article
- Polygenic risk scores and breast cancer risk prediction.Breast (Edinburgh, Scotland) · 2023Review
- Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.Human genomics · 2023Article
- Is loss of p53 a driver of ductal carcinoma in situ progression?British journal of cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.